Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chylomicron and Very Low-Density Lipoprotein Remnant Particles (Remnant Particles)
- Target
- Remnant Particles
- Molecular classification
- Lipoprotein, Triglyceride-rich lipoprotein
01
Overview
Chylomicron and VLDL remnant particles are triglyceride-rich lipoproteins formed after the partial lipolysis of chylomicrons and VLDL. These remnants are cholesterol ester-rich and are taken up by the liver via apoE-mediated receptor endocytosis. Elevated levels are highly atherogenic, contributing to cardiovascular disease by promoting arterial wall penetration, inflammation, and foam cell formation.
- Other names
- Chylomicron RemnantsVLDL RemnantsRemnant-like particle cholesterolRLP-C
02
Mechanism of action
Reducing remnant particle levels by increasing hepatic uptake, inhibiting apoCIII, or activating lipoprotein lipase.
03
Biological functions
Lipid transportCholesterol transportApoE-mediated hepatic uptakeDelivery of triglycerides to tissues
04
Disease associations
Cardiovascular diseaseAtherosclerosisHyperlipidemiaDyslipidemia
05
Safety considerations
Increased cardiovascular risk with elevated levelsPotential for off-target effects of drugs used to lower levels
06
Interacting drugs
Statins
5 more in the full profile.
07
Biomarkers
Remnant cholesterol (RC)Remnant-like particle cholesterol (RLP-C)ApoB48ApoB100Triglycerides
Beyond the preview
Go deeper on Chylomicron and Very Low-Density Lipoprotein Remnant Particles (Remnant Particles).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chylomicron and Very Low-Density Lipoprotein Remnant Particles (Remnant Particles).